# LM-302

Source: https://onco.cc/drugs/lm-302/  
OnCo record `lm-302` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

LM-302 is an experimental antibody-drug conjugate from LaNova Medicines Zhejiang in phase 3 trials for gastric & gastro-oesophageal junction cancer, aimed at Claudin 18.2.

## Summary

LM-302 is an antibody-drug conjugate developed by LaNova Medicines Zhejiang and Shanghai Chia Tai Tianqing Pharmaceutical Technology Development. Its target is Claudin 18.2 (the sponsor names CLDN18.2 (Claudin 18.2)). The sponsor states: LM-302 is an antibody-drug conjugate targeting CLDN18.2, evaluated in combination with tislelizumab versus tislelizumab plus chemotherapy in previously untreated, CLDN18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma. ClinicalTrials.gov describes the intervention as: The LM-302 injection is an ADC drug targeting CLDN18.2. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07385703 (Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma), in gastric & gastro-oesophageal junction cancer. The largest, NCT07385703, plans to enrol 752 participants with primary completion expected 2028-10. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: ADC
- Mechanism: LM-302 is an antibody-drug conjugate targeting CLDN18.2, evaluated in combination with tislelizumab versus tislelizumab plus chemotherapy in previously untreated, CLDN18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma.

## Sources

- ClinicalTrials.gov: trials of LM-302: https://clinicaltrials.gov/search?intr=LM-302

## Connected records

- cancers: [Claudin 18.2-positive gastric cancer](https://onco.cc/cancers/gastric-cldn18-2-positive/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- targets: [Claudin 18.2](https://onco.cc/targets/cldn18-2/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)
- trials: [A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study](https://onco.cc/trials/nct05934331/), [Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma](https://onco.cc/trials/nct07385703/), [Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer](https://onco.cc/trials/nct07108504/)

---
JSON: https://onco.cc/api/v1/entities/lm-302.json